For instance, drug repositioning has already identified up to 16 preexisting drugs that target transcription factors associated with NSCLC-related genes [12–14], current studies propose mitoxantrone and abacavir as ALK-targeting for NSCLC [15]. Here, ALK is linked to non-small cell lung carcinoma.